Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

File Description SizeFormat 
Psilodep_1_main_paper.pdfPublished version591.77 kBAdobe PDFDownload
Title: Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Author(s): Carhart-Harris, RL
Bolstridge, M
Day, CMJ
Rucker, J
Watts, R
Erritzoe, DE
Kaelen, M
Giribaldi, B
Bloomfield, M
Pilling, S
Rickard, JA
Forbes, B
Feilding, A
Taylor, D
Curran, HV
Nutt, DJ
Item Type: Journal Article
Abstract: RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure. RESULTS: Treatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen's d = 2.2 at week 1 and 2.3 at week 5, both p < 0.001); nine and four patients met the criteria for response and remission at week 5. Results remained positive at 3 and 6 months (Cohen's d = 1.5 and 1.4, respectively, both p < 0.001). No patients sought conventional antidepressant treatment within 5 weeks of psilocybin. Reductions in depressive symptoms at 5 weeks were predicted by the quality of the acute psychedelic experience. CONCLUSIONS: Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Psilocybin represents a promising paradigm for unresponsive depression that warrants further research in double-blind randomised control trials.
Publication Date: 8-Nov-2017
Date of Acceptance: 19-Oct-2017
URI: http://hdl.handle.net/10044/1/54802
DOI: https://dx.doi.org/10.1007/s00213-017-4771-x
ISSN: 0033-3158
Publisher: Springer Verlag
Start Page: 399
End Page: 408
Journal / Book Title: Psychopharmacology
Volume: 235
Issue: 2
Sponsor/Funder: Medical Research Council (MRC)
Funder's Grant Number: MR/J00460X/1
Copyright Statement: © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Science & Technology
Life Sciences & Biomedicine
Neurosciences
Pharmacology & Pharmacy
Psychiatry
Neurosciences & Neurology
Serotonin
5-HT2AR
Depression
Treatment-resistant depression
Psilocybin
Psychedelic
Mood
Hallucinogen
Psychotherapy
LYSERGIC-ACID DIETHYLAMIDE
LIFE-THREATENING CANCER
RECURRENT DEPRESSION
CONTROLLED-TRIALS
DISORDER
ANXIETY
LSD
ANTIDEPRESSANTS
PSYCHEDELICS
AUGMENTATION
5-HT2AR
Depression
Hallucinogen
Mood
Psilocybin
Psychedelic
Psychotherapy
Serotonin
Treatment-resistant depression
5-HT2AR
Depression
Hallucinogen
Mood
Psilocybin
Psychedelic
Psychotherapy
Serotonin
Treatment-resistant depression
11 Medical And Health Sciences
17 Psychology And Cognitive Sciences
Psychiatry
Publication Status: Published
Appears in Collections:Department of Medicine
Faculty of Medicine



Items in Spiral are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons